OBJECTIVES: To establish an evidence-based cut-off to differentiate between early and late recurrence and to compare clinicopathologic risk factors between the two groups. SUMMARY BACKGROUND DATA: A clear definition of "early recurrence" after pancreatic ductal adenocarcinoma resection is currently lacking. METHODS: Patients undergoing pancreatectomy for pancreatic ductal adenocarcinoma between 2000 and 2013 were included. Exclusion criteria were neoadjuvant therapy and incomplete follow-up. A minimum P-value approach was used to evaluate the optimal cut-off value of recurrence-free survival to divide the patients into early and late recurrence cohorts based on subsequent prognosis. Potential risk factors for early recurrence were assessed with logistic regression models. RESULTS: Of 957 included patients, 204 (21.3%) were recurrence-free at last follow-up. The optimal length of recurrence-free survival to distinguish between early (n = 388, 51.5%) and late recurrence (n = 365, 48.5%) was 12 months (P < 0.001). Patients with early recurrence had 1-, and 2-year post-recurrence survival rates of 20 and 6% compared with 45 and 22% for the late recurrence group (both P < 0.001). Preoperative risk factors for early recurrence included a Charlson age-comorbidity index ≥4 (OR 1.65), tumor size > 3.0 cm on computed tomography (OR 1.53) and CA 19-9 > 210 U/mL (OR 2.30). Postoperative risk factors consisted of poor tumor differentiation grade (OR 1.66), microscopic lymphovascular invasion (OR 1.70), a lymph node ratio > 0.2 (OR 2.49), and CA 19-9 > 37 U/mL (OR 3.38). Adjuvant chemotherapy (OR 0.28) and chemoradiotherapy (OR 0.29) were associated with a reduced likelihood of early recurrence. CONCLUSION: A recurrence-free interval of 12 months is the optimal threshold for differentiating between early and late recurrence, based on subsequent prognosis.
OBJECTIVES: To establish an evidence-based cut-off to differentiate between early and late recurrence and to compare clinicopathologic risk factors between the two groups. SUMMARY BACKGROUND DATA: A clear definition of "early recurrence" after pancreatic ductal adenocarcinoma resection is currently lacking. METHODS: Patients undergoing pancreatectomy for pancreatic ductal adenocarcinoma between 2000 and 2013 were included. Exclusion criteria were neoadjuvant therapy and incomplete follow-up. A minimum P-value approach was used to evaluate the optimal cut-off value of recurrence-free survival to divide the patients into early and late recurrence cohorts based on subsequent prognosis. Potential risk factors for early recurrence were assessed with logistic regression models. RESULTS: Of 957 included patients, 204 (21.3%) were recurrence-free at last follow-up. The optimal length of recurrence-free survival to distinguish between early (n = 388, 51.5%) and late recurrence (n = 365, 48.5%) was 12 months (P < 0.001). Patients with early recurrence had 1-, and 2-year post-recurrence survival rates of 20 and 6% compared with 45 and 22% for the late recurrence group (both P < 0.001). Preoperative risk factors for early recurrence included a Charlson age-comorbidity index ≥4 (OR 1.65), tumor size > 3.0 cm on computed tomography (OR 1.53) and CA 19-9 > 210 U/mL (OR 2.30). Postoperative risk factors consisted of poor tumor differentiation grade (OR 1.66), microscopic lymphovascular invasion (OR 1.70), a lymph node ratio > 0.2 (OR 2.49), and CA 19-9 > 37 U/mL (OR 3.38). Adjuvant chemotherapy (OR 0.28) and chemoradiotherapy (OR 0.29) were associated with a reduced likelihood of early recurrence. CONCLUSION: A recurrence-free interval of 12 months is the optimal threshold for differentiating between early and late recurrence, based on subsequent prognosis.
Authors: Joshua G Barton; John P Bois; Michael G Sarr; Christina M Wood; Rui Qin; Kristine M Thomsen; Michael L Kendrick; Michael B Farnell Journal: J Gastrointest Surg Date: 2009-09-09 Impact factor: 3.452
Authors: S W L de Geus; D B Evans; L A Bliss; M F Eskander; J K Smith; R A Wolff; R A Miksad; M C Weinstein; J F Tseng Journal: Eur J Surg Oncol Date: 2016-08-09 Impact factor: 4.424
Authors: Alexander A Parikh; Amelia Maiga; David Bentrem; Malcolm H Squires; David A Kooby; Shishir K Maithel; Sharon M Weber; Clifford S Cho; Matthew Katz; Robert C Martin; Charles R Scoggins; Jeff Sutton; Syed A Ahmad; Daniel E Abbott; Jacquelyn Carr; Hong Jin Kim; Danny Yakoub; Kamran Idrees; Nipun Merchant Journal: J Am Coll Surg Date: 2016-02-16 Impact factor: 6.113
Authors: Wenchuan Wu; Jin He; John L Cameron; Martin Makary; Kevin Soares; Nita Ahuja; Neda Rezaee; Joseph Herman; Lei Zheng; Daniel Laheru; Michael A Choti; Ralph H Hruban; Timothy M Pawlik; Christopher L Wolfgang; Matthew J Weiss Journal: Ann Surg Oncol Date: 2014-04-26 Impact factor: 5.344
Authors: Marco Niedergethmann; Ralf Hildenbrand; Birgit Wostbrock; Mark Hartel; Jörg W Sturm; Axel Richter; Stefan Post Journal: Pancreas Date: 2002-08 Impact factor: 3.327
Authors: O Turrini; C M Schmidt; J Moreno; P Parikh; J M Matos; M G House; N J Zyromski; A Nakeeb; H A Pitt; K D Lillemoe Journal: J Gastrointest Surg Date: 2009-05-21 Impact factor: 3.452
Authors: Asmita Chopra; Mazen Zenati; Melissa E Hogg; Herbert J Zeh; David L Bartlett; Nathan Bahary; Amer H Zureikat; Joal D Beane Journal: Ann Surg Oncol Date: 2021-05-23 Impact factor: 5.344
Authors: Nadege Fackche; Ryan K Schmocker; Boateng Kubi; Jordan M Cloyd; Ahmed Ahmed; Travis Grotz; Jennifer Leiting; Keith Fournier; Andrew J Lee; Benjamin Powers; Sean Dineen; Jula Veerapong; Joel M Baumgartner; Callisia Clarke; T Clark Gamblin; Sameer H Patel; Vikrom Dhar; Ryan J Hendrix; Laura Lambert; Daniel E Abbott; Courtney Pokrzywa; Kelly Lafaro; Byrne Lee; Mohammad Y Zaidi; Shishir K Maithel; Fabian M Johnston; Jonathan B Greer Journal: J Gastrointest Surg Date: 2021-02-25 Impact factor: 3.452
Authors: Vincent P Groot; Georgios Gemenetzis; Alex B Blair; Ding Ding; Ammar A Javed; Richard A Burkhart; Jun Yu; Inne H Borel Rinkes; I Quintus Molenaar; John L Cameron; Elliot K Fishman; Ralph H Hruban; Matthew J Weiss; Christopher L Wolfgang; Jin He Journal: Ann Surg Oncol Date: 2018-06-14 Impact factor: 5.344